Last reviewed · How we verify
AN2728 Ointment
AN2728 is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in immune cells.
AN2728 is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in immune cells. Used for Atopic dermatitis, Psoriasis.
At a glance
| Generic name | AN2728 Ointment |
|---|---|
| Also known as | AN2728 Ointment, 5% |
| Sponsor | Pfizer |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
PDE4 inhibition increases intracellular cAMP levels, which suppresses the production of pro-inflammatory mediators such as TNF-α and IL-2 from T cells and other immune cells. This mechanism reduces skin inflammation and is being developed for topical treatment of inflammatory skin conditions.
Approved indications
- Atopic dermatitis
- Psoriasis
Common side effects
- Application site irritation
- Headache
- Nasopharyngitis
Key clinical trials
- Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (PHASE4)
- Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (PHASE4)
- Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis (PHASE3)
- Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. (NA)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Eucrisa for Atopic Dermatitis (PHASE1)
- Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PHASE4)
- Topical Crisaborole in Patients with Alopecia Areata (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |